BackConduit Pharmaceuticals- Warrants (22/09/2028) Overview

Conduit Pharmaceuticals- Warrants (22/09/2028) Other Current Liabilities

Conduit Pharmaceuticals- Warrants (22/09/2028)'s other current liabilities is $290M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$293.60M
5.82% YoYΔ $-18.13M vs prior year quarter

Peer trimmed avg / median

Loading

Conduit Pharmaceuticals- Warrants (22/09/2028) Other Current Liabilities History

Loading

Conduit Pharmaceuticals- Warrants (22/09/2028) vs. peers: Other Current Liabilities Comparison

Loading

Conduit Pharmaceuticals- Warrants (22/09/2028) Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Conduit Pharmaceuticals- Warrants (22/09/2028) (CDTTW) FAQ

The latest other current liabilities for CDTTW is $290M as of June 2026. That compares with $310M in the prior-year period — down 5.8% year over year. Investors often review this figure alongside Conduit Pharmaceuticals- Warrants (22/09/2028)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, CDTTW's other current liabilities moved from $310M to $290M — a 5.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Conduit Pharmaceuticals- Warrants (22/09/2028)'s operating scale or balance-sheet position.

A other current liabilities figure of $290M for CDTTW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CDTTW's other current liabilities ($290M), review year-over-year change from $310M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.